



Development of Atlantic Salmon (Salmo salar L.) Under Hypoxic Conditions Induced Sustained Changes in Expression of Immune Genes and Reduced Resistance to Moritella viscosa

Aleksei Krasnov^{1*}, Erik Burgerhout¹, Hanne Johnsen^{1,2}, Helge Tveiten^{1,3}, Anne F. Bakke⁴, Hege Lund⁴, Sergey Afanasyev⁵, Alexander Rebl⁶ and Lill-Heidi Johansen¹

¹ Nofima AS, Tromsø, Norway, ² Fram Centre, Norwegian Polar Institute, Tromsø, Norway, ³ UIT The Arctic University of Norway, Tromsø, Norway, ⁴ Faculty of Veterinary Medicine, Norwegian University of Life Sciences, Oslo, Norway, ⁵ I. M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Saint-Petersburg, Russia, ⁶ The Leibniz Institute for Farm Animal Biology, Dummerstorf, Germany

OPEN ACCESS

Edited by:

Elisabeth Holen, Norwegian Institute of Marine Research (IMR), Norway

Reviewed by:

Lindsey Moore, University of Bergen, Norway Khalil Eslamloo, Memorial University of Newfoundland, Canada

> *Correspondence: Aleksei Krasnov Aleksei.Krasnov@nofima.no

Specialty section:

This article was submitted to Ecophysiology, a section of the journal Frontiers in Ecology and Evolution

> Received: 08 June 2021 Accepted: 12 July 2021 Published: 02 August 2021

Citation:

Krasnov A, Burgerhout E, Johnsen H, Tveiten H, Bakke AF, Lund H, Afanasyev S, Rebl A and Johansen L-H (2021) Development of Atlantic Salmon (Salmo salar L.) Under Hypoxic Conditions Induced Sustained Changes in Expression of Immune Genes and Reduced Resistance to Moritella viscosa. Front. Ecol. Evol. 9:722218. doi: 10.3389/fevo.2021.722218 Atlantic salmon is characterized with high sensitivity to low dissolved oxygen (DO) levels. Hypoxia can affect diverse biological processes with consequences that can be manifested immediately or with delay. Effects of hypoxia on the immune system and the resistance to a bacterial pathogen were investigated. Two groups were reared at, respectively, normal (NO, 80-100%) and low (LO, 60%) levels of DO over 10 months after which both groups were reared at NO. Smoltification was initiated after 13 months by a winter signal for 6 weeks, followed by constant light for 6 weeks. Samples were collected at the start and end of the constant light period. Expression of 92 immune and stress genes was analyzed in the gill, head kidney, and spleen using a Biomark HD. Most of differentially expressed genes showed higher levels in LO fish compared to NO fish; many immune genes were downregulated during smoltification and these changes were stronger in NO fish. A notable exception was pro-inflammatory genes upregulated in gill of NO fish. Further, salmon were challenged with Moritella viscosa, the causative agent of winter ulcer. Mortality was registered from 5 days post infection (dpi) to the end of trial at 36 dpi. Survival was consistently higher in NO than LO fish, reaching a maximum difference of 18% at 21-23 dpi that reduced to 10% at the end. Analyses with a genome-wide microarray at 36 dpi showed strong responses to the pathogen in gill and spleen. Notable features were the stimulation of eicosanoid metabolism, suggesting an important role of lipid mediators of inflammation, and the downregulation of chemokines. Many immune effectors were activated, including multiple lectins and acute phase proteins, enzymes producing free radicals, and matrix metalloproteinases. The transcriptomic changes induced with a bacterial challenge were similar in NO and LO. After the challenge, interferons a and g and panel of genes of innate antiviral immunity showed higher expression in LO, especially in the gill. The results from the

1

present study suggest that chronic hypoxia in early life stimulated immune genes and attenuated their downregulation associated with smoltification. However, these changes did not improve protection against a bacterial pathogen of major concern in salmon aquaculture.

Keywords: Atlantic salmon, hypoxia, development, immune response, transcriptomics, Moritella viscosa

INTRODUCTION

Salmonid species are evolutionarily adapted to pristine habitats with cold water and are characterized with high oxygen requirements and sensitivity to oxygen deficiency (Davis, 1975; Metcalfe et al., 1995; Remen et al., 2013). Hypoxic [low dissolved oxygen (DO) levels] conditions are often encountered in nature as well as in aquaculture environments. As DO levels play a crucial role in the maintenance of many biochemical and physiological processes, hypoxia can negatively affect development, growth, reproduction, and survival (Randall et al., 1982; Greig et al., 2006; Wang et al., 2009, 2016). The risk of hypoxia is especially high in the production units with a forced water supply including recirculation aquaculture systems (RAS) and in sea cages with large stocking densities (Remen et al., 2013; Kolarevic et al., 2016).

There is a constantly growing interest regarding the effects of hypoxia on the development, performance, and robustness of Atlantic salmon, which is associated with the expanding use of RAS in commercial aquaculture and expected climate change leading to an increase of water temperature in the sea. Many recent publications have addressed direct and remote consequences of low oxygen levels on Atlantic salmon with the observed effects ranging from complete recovery to significant changes. Daily cyclic hypoxia over 23 days with DO levels of 70% and below significantly reduced feed intake in postsmolts (Remen et al., 2012), and a 120 day exposure to low oxygen levels in large (1.5-2 kg) post-smolts showed a significant reduction in growth performance, and gene expression of liver tissue indicated clear effects of hypoxia on metabolic and protein catabolic pathways (Olsvik et al., 2013). Also, a cumulative effect of high temperature and hypoxia was found on growth and feed consumption in post-smolts (Gamperl et al., 2020). Interestingly, through metabolic measurements by swimming trials, it was suggested that especially smaller salmon (200 g) may be more vulnarable to hypoxia (50%) than their larger counterparts (3.5 kg; Oldham et al., 2019). Exposure to hypoxia from fertilization until start feeding did not appear to influence tolerance to hypoxia later in life (Wood et al., 2019, 2020).

A number of studies have focused on the immediate effects of hypoxia on disease resistance and expression of immune genes in salmonid fish. For example, hypoxia appeared not to differentially affect the severity of pancreas disease in salmon infected with salmonid alphavirus (Andersen et al., 2010). On the other hand, in Atlantic salmon post-smolts infected with amoebe *Neoparamoeba perurans* (the agent of amoebic gill disease), cyclic hypoxia accelerated the progression of the disease and increased amoeba counts and mortality (Oldham et al., 2020). Niklasson et al. (2011) showed that low DO levels affected the mucosal immune system of the intestine, through downregulations of nuclear factor kappa B, and differential expression of interleukins in combination with higher temperature. Furtermore, chronic hypoxia (~50% DO) in Atlantic salmon post-smolts resulted in a distinct change of the immune response toward a viral or bacterial challenge in vitro as well as in vivo (Kvamme et al., 2013). Although the response to a bacterial challenge somewhat differed between the normoxic control and hypoxic groups, Atlantic salmon were able to mount a strong innate immune response (Zanuzzo et al., 2020). In Oncorhynchus kisutch, hypoxia generated a cortisol stress response \leq 35% DO levels and several toll-like receptors and cytokines of the innate and adaptive immune response were differentially regulated (Martínez et al., 2020). Transcriptome analyses revealed combined effects of hypoxia and high water temperature (20°C) on hepatic expression of immune and stress genes in Atlantic salmon (Beemelmanns et al., 2021).

We report the immune changes induced in early development and manifested over a long period. Recently, our group showed the effects of hypoxia during early life stages on the transcriptome in start feeding larvae of Atlantic salmon (Kelly et al., 2020). This research was performed as a part of a large trial that investigated the programming effects of the environment during early life. In the present follow-up study, we investigated the prolonged effects of early life stage hypoxia. Two study groups reared at 60 and 80-100% saturation of DO were compared by the expression of 92 immune and stress genes using a test developed for assessment of the immune competence of Atlantic salmon on BioMark HD platform - ImCom (Krasnov et al., 2020). Further, challenge with Moritella viscosa, a causative agent of winter ulcer (Løvoll et al., 2009), was followed with transcriptome analyses. Despite widespread vaccination with multi-component vaccines containing the M. viscosa antigen, disease outbreaks continue to be reported in high numbers in seawater reared Atlantic salmon in Norway (Karlsen et al., 2017).

MATERIALS AND METHODS

Fish: Experimental Procedures and Sampling

All fish handling procedures employed in the study were in accordance with national (Approval ID 11814) and EU legislation (2010/63/EU) on animal experimentation. Directly after fertilization, Atlantic salmon (AquaGen strain) eggs were kept at 60% (LO) and 80–100% NO DO levels for approximately 10 months (**Figure 1**). Oxygen levels above 80% are relevant to aquaculture operation and do not affect salmon growth. Eggs



from each of the two groups were kept in triplicate tanks (for more details, see Kelly et al., 2020). After 10 months, the fish were PIT-tagged for individual identification and kept at 80-100% DO. At 14 months, smoltification was induced by the following light regimen: 6 weeks of 18 h darkness and 6 h light (winter), followed by 6 weeks of 24 h light (summer). Temperature during the first month after hatching was 7°C, after that the fish were kept at 10°C for the rest of the experimental period. The smoltification process was followed by seawater challenge tests (n = 10 per group) at 0, 3, and 6 weeks after the start of summer period. After 24 h, they were sacrificed using an overdose of Benzoak (0.3 mL/L) and blood was sampled for serum cortisol concentration and gill Na ATPase activity (Eurofins) analyses, to assess the development of hypo-osmoregulatory capacity. Both groups were adapted to seawater after the summer period, and no difference in plasma cortisol levels and ATPase activity was observed between the groups during smoltification. In the part of the trial described here, a total of 276 fish were used: 60 for the seawater challenge tests and 216 fish for the following bacterial challenge test. No mortalities were registered before the bacterial challenge test was started. No significant weight differences between the two groups were registered during the experimental period.

A bacterial challenge test with M. viscosa was performed after smoltification, at 17 months and at mean weight 81.2 ± 10.2 g. A total of 108 fish from each of the two groups were transferred to seawater in two 900-l circular tanks, 54 fish from each group per tank, at 10°C, and acclimated for 5 days before bath challenge (stagnant water, density 52 kg/m³, oxygenated, duration 1 h) with M. viscosa (LFI5006/2), originally isolated from the head kidney of farmed Atlantic salmon in northern Norway suffering from winter ulcer. Bacteria from frozen stock culture were grown at 12°C on blood agar (Oxoid) with 2% NaCl for 48 h and single colonies transferred to 20 ml Marine Broth (2216 Difco) and grown for 48 h at 12°C with shaking before inoculation of 600 ml MB and further growth for 48 h at 12°C. Before challenge, the OD_{600 nm} was measured and challenge dose used was 10⁷ cfu/ml. Challenge dose was confirmed by titration of the bacterial culture used for challenge on blood agar plates with 2% NaCl and counting of colonies. After the end of bath challenge, the fish were kept in running water at 10°C and density ca 30 kg/m³. Any background mortality during the challenge experiment was monitored in uninfected fish from the same groups and kept under the same conditions as the infected fish.

Samples of gill, head kidney, and spleen were collected, at day 0 (start of continuous light of the smoltification process), day 42 of light stimulation (smolts), and 5 days before pathogen challenge, and at the end of the challenge trial. Mortality was registered for 36 days. Verification of *M. viscosa* as the cause of death was done by gross pathology (specifically wound development) and isolation of the pathogen from the head kidney samples of moribund fish on blood agar with 2% NaCl. At termination, all fish from the two tanks were scored for wounds, and 30 fish from each tank (five per group) were sampled for blood (plasma, erythrocytes), gill, skin, head kidney, and spleen in RNAlater.

RNA Isolation

Total RNA and DNA were isolated and purified using AllPrep DNA/RNA/miRNA Universal Kit (Qiagen) according to the manufacturer's protocol. RNA quantity and quality were determined with Nanodrop (Thermo Scientific) and Bioanalyzer (Agilent).

Multigene Expression Assay

To assess the immune competence (ImCom) of Atlantic salmon smolts and growers, a multigene expression assay representing the key functional groups of the immune system was designed on Biomark HD platform (Fluidigm; Krasnov et al., 2020). The first version of ImCom was used that includes 92 immune and stress genes, which were selected by the expression profiles in many challenge trials with pathogens and under inflammatory conditions, and reference genes. Analyses were performed in the gill, spleen, and head kidney of fish collected at the start and end of constant light stimulation (days 0 and 42, n = 6, totally 72 samples). The extracted RNA was adjusted at 10 ng/5 μ l and reverse-transcribed using the Reverse transcription master mix (Fluidigm). Subsequently, the individual cDNA samples were added to the aforementioned 96 primer pairs (100 μ M) and the PreAmp master mix (Fluidigm) and subjected to 12 preamplification cycles in a standard thermocycler (TAdvanced, Biometra). The pre-amplified products were treated with exonuclease I (New England BioLabs) and diluted in a SoFast EvaGreen supermix with Low ROX (Bio-Rad) and 20× DNAbinding dye sample loading reagent. The sample and primer mixes were transferred to the respective inlets of two 48.48 dynamic array IFC chips. These chips were individually primed in the BioMark IFC controller MX (Fluidigm) according to the Load mix 48.48 GE script. The loaded array chips were then placed in

the BioMark HD system (Fluidigm) to proceed with the qPCR according to the GE 48 × 48 Fast PCR + Melt v2.pcl cycling program. Fluidigm RealTime PCR analysis software v. 3.0.2 was used to retrieve raw qPCR results, which were transferred in a relational database. The geometric means of two reference genes: *elongation factor 1-alpha 1* and 40s *ribosomal protein s20 (eef1a1b* and *rps20)*, which showed stability across samples, were used for calculation of Δ Ct values. Further, the average for each gene was calculated for the entire data set and subtracted from each data point. Differential expression between the treatment groups and time-points was assessed by criteria: difference of $\Delta\Delta$ Ct > | 0.8| and *p* < 0.05 (*t*-test).

Microarray

Transcriptome analyses were carried out on gill and spleen of uninfected and challenged salmon with Nofima's Atlantic salmon genome-wide 42.5 k DNA oligonucleotide microarray Salgeno-2 (GPL28080), totally 41 microarrays were used (n = 5). Microarrays were manufactured by Agilent Technologies, and the reagents and equipment were purchased from the same provider. Genes are annotated in Nofima's bioinformatic pipeline STARS using GO, KEGG, and custom vocabulary (Krasnov et al., 2011a). RNA amplification and labeling were performed with a One-Color Quick Amp Labeling Kit and a Gene Expression Hybridization kit was used for fragmentation of labeled RNA. Total RNA input for each reaction was 500 ng. After overnight hybridization in an oven (17 h, 65°C, rotation speed 0.01 g), arrays were washed with Gene Expression Wash Buffers 1 and 2 and scanned with Agilent scanner. Subsequent data analyses were carried out with STARS. Global normalization was performed by equalizing the mean intensities of all microarrays. The individual values for each feature were divided by the mean value of all samples thus producing expression ratios (ER). The log₂-ER were calculated and normalized with the locally weighted non-linear regression (Lowess). The differentially expressed genes (DEG) were selected by criteria: \log_2 -ER > 0.8 (1.75-fold) and p < 0.05(t-test). Enrichment of functional categories of gene Ontology (GO) was evaluated by comparing the numbers of genes per term in the lists of DEG, and on the microarray platform, significance

was assessed with Yates' corrected chi-square test. Data were submitted to NCBI GEO Omnibus (GSE171693).

RESULTS

Expression of Immune Genes in Uninfected Salmon

The expression profiles of immune and stress genes in the lymphatic organs and gill were overall similar although the numbers and composition of DEG varied (Figures 2, 3). At day 0, the numbers of immune genes with lower expression in NO compared to LO ranged from 11 genes in the spleen to 19 genes in the head kidney and gill, while only one gene was upregulated in the spleen. During smoltification, many immune genes were downregulated, which is in concordance with our previous observations (Johansson et al., 2016; Robinson et al., 2017; Karlsen et al., 2018). The number of genes with decreased expression at day 42 was larger in tissues of salmon that had not been exposed to hypoxia: 42 versus 14 genes in the spleen and 28 versus 7 genes in the gill. Similar numbers of genes were downregulated in the head kidneys of LO and NO and only a few genes showed significant difference between the treatment groups at day 42, which was explained with high variance in LO. Although the decrease of expression in the end of smoltification clearly prevailed, a suite of genes showed upregulation at day 42, especially in the gill (Figure 3). A group of 15 genes included several markers of acute inflammation, such as chemokine lect2 (Mutoloki et al., 2010), a component of oxidative burst complex neutrophil cytosolic factor 1 and collagen degrading matrix metalloproteinases mmp9 and mmp13. Macrophage receptor marco (Poynter et al., 2017) and immunoglobulin receptor are involved in phagocytosis. Upregulation of these genes has been observed in Atlantic salmon under various diseases and inflammatory conditions (submitted manuscript). At day 0, the mean expression was 1.9-fold higher in LO. This group also showed a smaller reduction associated with smoltification (1.9fold in NO and 1.5-fold in LO), the difference between the groups increased to 2.4-fold at day 42.





TIME	Group	Tissue	Gene	D0 NO	DOLO	D42 NO	D42 L0	Function	Time	Group	Tissue	Gene	D0 NO	DOLO	D42 NO	D42 L
NO	D42	Gill	C-C motif chemokine 20-like	2.21	1.81	-6.37	1.50	Polyamine		D0,D42	Gill	Diamine acetyltransferase 1	-0.48	0.94	-1.19	0.50
NO	D42	Gill	TNF decoy receptor	1.15	1.86	-5.49	0.84	Polyamine		DO	НК	Diamine acetyltransferase 1	-0.80	1.17	-0.51	0.44
NO	D42	Gill	IL-1 receptor type II	0.24	0.75	-2.01	0.81	Polyamine		D0,D42	Spleen	Diamine acetyltransferase 1	-1.13	0.96	-0.97	1.10
NO	D42	Gill	IL-10 receptor beta chain	0.29	0.25	-1.22	0.37	Effector	NO	D42	Gill	Ornithine decarboxylase 1	0.46	0.28	-1.35	0.60
NO	D42	Gill	Leukocyte cell-derived chemotaxin	-0.77	-0.40	3.91	-1.13	Iron & heme	NO	D0,D42	НК	Heme oxygenase	-0.15	0.44	-0.59	0.08
NO	D42	Gill	GCSF receptor	-0.65	-0.12	1.94	-0.72	Iron & heme	NO	D42	Spleen	Haptoglobin	0.47	1.53	-2.89	0.38
LO,NO	DO	Spleen	IL-8-like	1.55	0.61	-1.17	-0.64	lg receptor	NO	D42	Gill	Ig Fc receptor I	-0.16	0.23	2.22	-0.97
	D42	Spleen	CD40 (TNFR5)	-1.00	0.43	-0.88	1.13	Scavenger	NO	D42	Gill	Macrophage receptor MARCO	-1.07	0.40	1.81	-0.40
	DO	Spleen	Beta-2 microglobulin	-0.44	0.98	-0.90	-0.67	Protease	NO	D42	Gill	MMP-13 or Collagenase 3	-1.03	-0.29	2.32	-0.45
NO	D42	Gill	MHC class la heavy chain	0.15	1.39	-2.80	0.84	Protease	195	DO	НК	MMP-13 or Collagenase 3	0.07	1.31	-0.27	0.09
NO	D42	Gill	HLA class II histantigen	0.25	1.00	-2.50	0.75	Protease	NO	D42	Spleen	MMP-13 or Collagenase 3	0.93	1.29	-1.05	0.67
NO	D42	Gill	Beta-2 microglobulin	-0.18	0.95	-1.99	0.43	Protease	NO	D42	Gill	MMP-9	-1.66	-0.98	2.96	-0.09
	D42	Gill	CD40 (TNFR5)	0.09	1.11	-1.13	0.38	Protease	LO	DO	НК	MMP-9	-0.21	1.58	-0.62	0.05
	DO	НК	CD40 (TNFR5)	-1.34	0.85	-0.53	0.89	Oxidative burst	NO	D42	Gill	Neutrophil cytosolic factor 1	-0.97	-0.85	3.92	-1.66
	DO	НК	MHC class la heavy chain	-0.43	0.95	-0.63	0.19	Oxidative burst		DO	НК	SH3 and PX domain-containing 2A	-0.42	1.36	-0.66	0.39
	DO	HK	Serum amyloid A-5	-1.35	0.06	-0.15	0.40	Oxidative burst	-	D0,D42	Spleen	SH3 and PX domain-containing 2A	-0.76	1.07	-1.09	0.46
	DO	НК	Apolipoprotein C-I	-0.37	1.56	-1.30	-0.38	Lectin	NO	D42	Gill	C type lectin receptor A	-0.91	-0.07	1.86	-0.1
NO	D42	Gill	Apolipoprotein C-I	1.09	1.94		1.27	Lectin	NO	D42	Gill	Snaclec 1-like	-0.01	0.65	-4.90	1.67
NO	D42	Gill	Differentially regulated protein 1	1.45	1.18	-4.73	1.36	Lectin	LO		Spleen	P-selectin	-0.49	0.48	-1.23	-0.04
NO	D0,D42	Spleen	Apolipoprotein C-I	-0.03	1.76	-2.39	-0.01	Lymphocyte		D0,D42	HK	SH2 domain-containing 1A	-0.61	0.53	-0.60	0.28
	DO	НК	Barrier-to-autointegration factor	-0.15	1.06	-0.42	0.28	Lymphocyte		DO	НК	CD28	-0.58	0.79	-0.55	0.31
NO	D42	Gill	Interferon regulatory factor 1 (irf1)	0.43	1.16	-2.36	0.70	Lymphocyte		DO	HK	CD4	-0.45	1.04	-0.87	0.31
NO,LO	D0,D42	Spleen	interferon alpha 2 (ifna2)	1.18	0.85	-1.71	-0.33	Lymphocyte		D0,D42	НК	CD152	-0.36	0.96	-0.99	0.02
		Spleen	interferon regulatory factor 1 (irf1)	-0.99	0.06	-0.42	0.42	Lymphocyte		DO	HK	TNFR superfamily member 14	0.04	1.12	-0.59	-0.07
NO,LO	D0,D42	Spleen	ISG15-like	0.62	1.27	-1.56	-0.56	Lymphocyte	NO	DO	HK	SAM and SH3 domai 3	0.10	0.41	-0.22	0.07
NO,LO	D0,D42	Spleen	Receptor transporting protein 2	1.22	0.79	-1.60	-0.35	Lymphocyte	NO	D42	Gill	CD83	1.45	0.83	-1.31	-0.11
NO		Spleen	Viperin	0.28	1.36	-2.38	-0.04	Lymphocyte	NO	DO	Spleen	CD152	0.48	1.57	-2.52	-0.41
NO	D0,D42	Gill	Complement component C4	0.13	0.73	-2.00	1.07	Lymphocyte	NO	D0,D42	Spleen	CD28	-0.13	1.34	-1.84	0.06
NO	D0,D42	НК	Complement component C4	-0.04	0.84	-0.77	-0.09	Lymphocyte	NO	D0,D42	Spleen	CD274 (PDL1)	-1.71	0.30	-0.50	0.57
NO	D42	Spleen	C1q-like adipose protein	0.01	1.00	-1.97	0.24	Lymphocyte	100	D42	Spleen	CD53	-0.32	0.90	-1.24	0.44
NO	D0,D42	Gill	Cathelicidin	0.03	1.48	-1.04	0.37	Regulator	NO	D0,D42	Gill	Kruppel-like factor 4b	-1.94	-0.18	1.90	0.18
	D42	НК	Cathelicidin	-0.08	1.11	-1.26	-0.26	Regulator	NO		Spleen	SOCS1	0.45	1.10	-2.13	-0.32
NO	D0,D42	Spleen	Cathelicidin	0.25	1.52	-2.54	0.46	Stress	NO	DO	НК	78 kDa glucose-regulated protein	-1.04	0.77	-0.19	0.37
	D42	Spleen	L-amino-acid oxidase	1.61	0.67	-0.54	-0.94	Stress	NO	D42	Spleen	78 kDa glucose-regulated protein	-1.38	0.05	-0.15	0.72
	D42	Gill	Arginase-2	-0.41	0.58	-1.49	0.75	Stress	NO,LO	D0,D42	Spleen	DNA-damage-inducible protein 4	1.39	0.82	-1.76	-0.2
	0 N0 N0 N0 N0 N0 N0 N0 N0 N0 N	NO D42 NO D42 NO D42 NO D42 NO D42 NO D42 D0 D42 NO D0,D42 NO D0,D42 NO D0,D42 NO D0,D42 NO D42 NO D42 NO D0,D42 P42 P42 P42 P42 P42 P42 </td <td>NO D42 Gill NO D42 Gill NO D42 Gill NO D42 Gill NO D42 Gill D0 Spleen D0 D0 Spleen D0 NO D42 Gill NO D0,042 Spleen NO D0,042 Spleen NO D0,042 Gill NO D0,042 Gill NO D0,042 Spleen NO D0,042</td> <td>NO D42 Gill IL-1 receptor type II NO D42 Gill IL-10 receptor beta chain NO D42 Gill GET receptor NO D42 GIII GET receptor NO D42 GIII GET receptor D42 Spleen IL-3-like D42 Spleen CAO (TMFR5) D0 Spleen CAO (TMFR5) D0 D42 GIII MHC class I histantigen NO D42 GIII MHC class I histantigen NO D42 GIII CD40 (TMFR5) D0 HK CD40 (TMFR5) D0 HK CD40 (TMFR5) D0 HK MHC class I histantigen NO D42 GIII Apolipoprotein C-1 NO D42 GIII Apolipoprotein C-1 NO D42 GIII Interferon regulatory factor 1 (irf1) NO D42 GIII Interferon regulatory factor 1 (irf1) OD <td< td=""><td>NO D42 Gill IL-1 receptor type II 0.24 NO D42 Gill IL-10 receptor type II 0.24 NO D42 Gill IL-10 receptor type II 0.24 NO D42 Gill Let.0 receptor beta chain 0.27 NO D42 Gill GEV totoptor beta chain 0.97 NO D42 Gill GEV totoptor beta chain 0.05 D42 Spleen CA0 (TNR5) 1.00 D0 Spleen CA0 (TNR5) 0.09 D0 D42 Gill HAC class I heravy chain 0.15 D0 D42 Gill CA0 (TNR5) 0.09 D0 HK Serum amyloid A-5 1.35 D0 HK MC class Ia heavy chain -0.43 D0 HK Serum amyloid A-5 1.35 D0 HK Serum amyloid A-5 1.35 NO D42 Gill Differentially regulated protein 1 1.45 NO D42</td><td>NO D42 Gill IL-1 receptor type II 0.24 0.75 NO D42 Gill IL-10 receptor type II 0.29 0.25 NO D42 Gill IL-10 receptor type II 0.29 0.25 NO D42 Gill IL-10 receptor type II 0.77 -0.40 NO D42 Gill GSF receptor -0.65 -0.12 DNO D0 Spleen IL-3/16 1.00 0.43 D0 Spleen Beta-2 microglobulin -0.44 0.98 NO D42 Gill HAL class II histantigen 0.25 1.00 NO D42 Gill HAL class II histantigen -0.25 1.00 NO D42 Gill D40 (TNFR5) -0.31 1.05 D0 HK CH4C (TNFR5) -0.37 1.56 D0 HK Serum amyloid A-5 1.39 0.06 D0 HK Mel class Ia heavy chain -0.43 0.95</td><td>NO D42 Gill IL-1 receptor ype II 0.24 0.75 -200 NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 NO D42 Gill GCSF receptor -0.77 -0.40 851 NO D42 Gill GCSF receptor -0.65 -0.12 194 D42 Spleen IL-8-like 1.56 0.61 1.17 D42 Spleen D40 (TIRFS) -0.00 0.43 0.98 -0.90 NO D42 Gill HAL class I histantigen 0.25 1.00 -2.50 NO D42 Gill Beta-2 microglobulin -0.18 0.95 -1.99 D42 Gill MAL class I histantigen 0.25 1.00 -2.50 NO D42 Gill Abolipoprotein C-1 -0.31 1.05 -1.50 D0 H</td><td>NO D42 Gill IL-1 receptor byte II 0.24 0.75 -201 0.81 NO D42 Gill IL-10 receptor byte achain 0.29 0.25 1.22 0.37 NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 0.37 NO D42 Gill Levkorte cell-derived chemotaxin 0.77 0.40 891 1113 NO D42 Gill GEV control of the set of t</td><td>NO D42 Gill IL-1 receptor ype II 0.24 0.75 201 0.81 Polyamine NO D42 Gill LL-10 receptor beta chain 0.29 0.25 1.22 0.37 Effector NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme D42 Spleen D47 (TNF6) -0.00 0.61 2.17 -0.64 Igreceptor D42 Spleen D47 (TNF6) -0.00 0.80 -0.90 -0.57 Protease NO D42 Gill HAL class II histamigen 0.25 1.00 2.50 0.75 Protease NO D42 Gill Editas II histamigen -0.38 0.65 -0.53 0.89 oxitative burst D0 HK D40 (TNF75) -0.34 0.85 -0.53 0.89 oxitative burst <</td><td>NO D42 Gill IL-1 receptor type II 0.24 0.75 2.00 0.81 Polyamine NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 0.37 Effector NO NO D42 Gill GCSF receptor -0.07 -0.40 3.91 Lill ron & heme NO NO D42 GIII GCSF receptor -0.07 -0.40 3.93 Lill ron & heme NO D0 Spleen IL-s-like 1.95 0.61 -1.17 -0.64 Igr receptor NO D04 Spleen D424 GIII MHC class Is heavy chain 0.15 1.39 -2.80 0.75 Protease NO NO D42 GIII HA class II histanifegan 0.25 1.00 -2.80 0.75 Protease NO NO D42 GIII CD40 (TNR5) 0.99 1.11 -1.11 0.38 Protease LO D0 HK</td><td>NO D42 Gill IL-1 receptor type II 0.24 0.75 -2.01 0.81 Polyamine D0.042 NO D42 Gill Le 10 receptor beta chain 0.29 0.25 3.22 0.37 Effector NO D42 NO D42 Gill Gell devocyte cell-derived chemotaxin -0.77 -0.40 8.91 4.113 fon & heme NO D0.042 NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 tron & heme NO D42 D42 Spleen IL4-silke 1.55 0.61 1.117 -0.64 Igreceptor NO D42 D42 Spleen D40 (TNR5) 1.00 -0.43 0.95 -0.67 Fortease NO D42 NO D42 Gill MHC class Is heavy chain 0.15 1.00 -2.50 0.75 Protease NO D42 NO D42 Gill MAtaisas I hibitatnifgen 0.25 1.</td><td>NO D42 Gill IL-1 receptor type II 0.24 0.75 -2.01 0.81 Polyamic D0,D42 Spleen NO D42 Gill LL-10 receptor beta chain 0.29 0.25 2.22 0.37 Effector NO D42 Gill NO D42 Gill Levkorte cell-derived chemotaxin -0.77 -0.40 8.93 113 Iron & heme NO D0,D242 HK NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Gill D42 Spleen L640 (TNR5) 100 0.43 0.98 1.13 Scavenger NO D42 Gill NO D42 Gill HA class I histamigen 0.25 1.00 -2.50 0.75 Protease NO D42 Gill NO D42 Gill MA class I histamigen 0.25 1.00 2.50 0.75 Protease NO D42</td><td>No De2 Gill Lit Is receptor type II 0.24 0.27 0.20 0.81 Polyamine D0, D42 Gill Ornithine acetyltransferase 1 NO D42 Gill Lit Droceptor beta chain 0.27 0.40 0.31 Effector NO D42 Gill CSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Spleen Lish Iter exceptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Spleen Lish Iter exceptor -0.65 -0.12 1.94 0.72 Iron & heme NO D42 Spleen Lish Iter exceptor -0.64 1.98 -0.64 Iter exceptor NO D42 Gill MMC Class I histantigen 0.15 1.39 -0.68 0.74 Protease NO D42 Gill MMP-13 or Collagenase 3 NO D42 Gill HAC Class I histantigen 0.15 1.39 2.80 0.48 Protease NO D42 Gilll MMP-13 or Collag</td><td>No De2 Gill Lif Jreceptor type II 0.24 0.25 -2.03 0.81 Polyamine D0.042 Spleen Diamine acceptransferase 1 113 NO D42 Gill Leukoropt obstachain 0.27 -0.20 0.37 Effector NO D42 Gill Continine decatbonylose 1 0.46 NO D42 Gill Leukoropt obstachain -0.77 -0.40 2.01 1.04 -0.65 -0.12 1.04 -0.64 greecptor NO D42 Spleen Legitor -0.65 -0.12 1.04 -0.64 greecptor NO D42 Gill Macrophage receptor MARCO 1.07 DA D42 Spleen Code (TNPR5) 1.00 -0.64 0.88 -0.64 precesse NO D42 Gill MMc12 classes 1.03 NO D42 Gill MMF-13 or Collagenase 3 0.037 NO D42 Gill D417 Classe In heav chain -0.18 0.05 Protease NO <t< td=""><td>No Del2 Gill IL:1 receptor type III 0.24 0.75 2.201 0.81 Polyamine D0,042 Spleen Diamine accety/transferase I 1.13 0.36 NO D42 Gill Leir receptor beta chain -0.77 -0.40 3.31 2.11 trans heme NO D0,042 Spleen Method constraints -0.46 0.32 NO D42 Gill Ledvocyte cell-derived chemotaxin -0.77 -0.40 3.31 1.11 form & heme NO D0,22 Spleen Haptoglobin -0.46 0.42 D42 Spleen Cody (TMFK5) -0.00 -0.43 Igr ecceptor NO D42 Gill Metro 3not collagenase 3 1.02 -0.40 NO D42 Gill Mid-class II histantigen 0.25 1.00 2.50 0.75 Protease NO D42 Gill MMP-30 or collagenase 3 0.07 1.31 NO D42 Gill Meta class II histantigen 0.25 1.03 2.53<!--</td--><td>No No Vest Gill IL:11 receptor type III 0.24 0.75 -0.20 0.81 Polyamine D0.042 Splen Diamine acceptionaferase I 1.13 0.96 0.97 NO 0.42 Gill Lit receptor beta chain 0.27 -0.40 2.91 Tron & heme NO 0.02 Splen Hetro organization 0.41 0.43 0.33 NO 0.42 Gill Levocyte cell-derived chemotaxin 4.07 4.04 2.92 Fore explori -0.46 1.82 4.03 4.04 1.81 3.03 0.83 0.85 1.13 Screenger NO 0.42 Gill Mercophage receptor MACO 1.01 3.02 3.03 4.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.04 7.03 7.04 7.03 7.04 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03</td></td></t<></td></td<></td>	NO D42 Gill D0 Spleen D0 D0 Spleen D0 NO D42 Gill NO D0,042 Spleen NO D0,042 Spleen NO D0,042 Gill NO D0,042 Gill NO D0,042 Spleen NO D0,042	NO D42 Gill IL-1 receptor type II NO D42 Gill IL-10 receptor beta chain NO D42 Gill GET receptor NO D42 GIII GET receptor NO D42 GIII GET receptor D42 Spleen IL-3-like D42 Spleen CAO (TMFR5) D0 Spleen CAO (TMFR5) D0 D42 GIII MHC class I histantigen NO D42 GIII MHC class I histantigen NO D42 GIII CD40 (TMFR5) D0 HK CD40 (TMFR5) D0 HK CD40 (TMFR5) D0 HK MHC class I histantigen NO D42 GIII Apolipoprotein C-1 NO D42 GIII Apolipoprotein C-1 NO D42 GIII Interferon regulatory factor 1 (irf1) NO D42 GIII Interferon regulatory factor 1 (irf1) OD <td< td=""><td>NO D42 Gill IL-1 receptor type II 0.24 NO D42 Gill IL-10 receptor type II 0.24 NO D42 Gill IL-10 receptor type II 0.24 NO D42 Gill Let.0 receptor beta chain 0.27 NO D42 Gill GEV totoptor beta chain 0.97 NO D42 Gill GEV totoptor beta chain 0.05 D42 Spleen CA0 (TNR5) 1.00 D0 Spleen CA0 (TNR5) 0.09 D0 D42 Gill HAC class I heravy chain 0.15 D0 D42 Gill CA0 (TNR5) 0.09 D0 HK Serum amyloid A-5 1.35 D0 HK MC class Ia heavy chain -0.43 D0 HK Serum amyloid A-5 1.35 D0 HK Serum amyloid A-5 1.35 NO D42 Gill Differentially regulated protein 1 1.45 NO D42</td><td>NO D42 Gill IL-1 receptor type II 0.24 0.75 NO D42 Gill IL-10 receptor type II 0.29 0.25 NO D42 Gill IL-10 receptor type II 0.29 0.25 NO D42 Gill IL-10 receptor type II 0.77 -0.40 NO D42 Gill GSF receptor -0.65 -0.12 DNO D0 Spleen IL-3/16 1.00 0.43 D0 Spleen Beta-2 microglobulin -0.44 0.98 NO D42 Gill HAL class II histantigen 0.25 1.00 NO D42 Gill HAL class II histantigen -0.25 1.00 NO D42 Gill D40 (TNFR5) -0.31 1.05 D0 HK CH4C (TNFR5) -0.37 1.56 D0 HK Serum amyloid A-5 1.39 0.06 D0 HK Mel class Ia heavy chain -0.43 0.95</td><td>NO D42 Gill IL-1 receptor ype II 0.24 0.75 -200 NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 NO D42 Gill GCSF receptor -0.77 -0.40 851 NO D42 Gill GCSF receptor -0.65 -0.12 194 D42 Spleen IL-8-like 1.56 0.61 1.17 D42 Spleen D40 (TIRFS) -0.00 0.43 0.98 -0.90 NO D42 Gill HAL class I histantigen 0.25 1.00 -2.50 NO D42 Gill Beta-2 microglobulin -0.18 0.95 -1.99 D42 Gill MAL class I histantigen 0.25 1.00 -2.50 NO D42 Gill Abolipoprotein C-1 -0.31 1.05 -1.50 D0 H</td><td>NO D42 Gill IL-1 receptor byte II 0.24 0.75 -201 0.81 NO D42 Gill IL-10 receptor byte achain 0.29 0.25 1.22 0.37 NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 0.37 NO D42 Gill Levkorte cell-derived chemotaxin 0.77 0.40 891 1113 NO D42 Gill GEV control of the set of t</td><td>NO D42 Gill IL-1 receptor ype II 0.24 0.75 201 0.81 Polyamine NO D42 Gill LL-10 receptor beta chain 0.29 0.25 1.22 0.37 Effector NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme D42 Spleen D47 (TNF6) -0.00 0.61 2.17 -0.64 Igreceptor D42 Spleen D47 (TNF6) -0.00 0.80 -0.90 -0.57 Protease NO D42 Gill HAL class II histamigen 0.25 1.00 2.50 0.75 Protease NO D42 Gill Editas II histamigen -0.38 0.65 -0.53 0.89 oxitative burst D0 HK D40 (TNF75) -0.34 0.85 -0.53 0.89 oxitative burst <</td><td>NO D42 Gill IL-1 receptor type II 0.24 0.75 2.00 0.81 Polyamine NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 0.37 Effector NO NO D42 Gill GCSF receptor -0.07 -0.40 3.91 Lill ron & heme NO NO D42 GIII GCSF receptor -0.07 -0.40 3.93 Lill ron & heme NO D0 Spleen IL-s-like 1.95 0.61 -1.17 -0.64 Igr receptor NO D04 Spleen D424 GIII MHC class Is heavy chain 0.15 1.39 -2.80 0.75 Protease NO NO D42 GIII HA class II histanifegan 0.25 1.00 -2.80 0.75 Protease NO NO D42 GIII CD40 (TNR5) 0.99 1.11 -1.11 0.38 Protease LO D0 HK</td><td>NO D42 Gill IL-1 receptor type II 0.24 0.75 -2.01 0.81 Polyamine D0.042 NO D42 Gill Le 10 receptor beta chain 0.29 0.25 3.22 0.37 Effector NO D42 NO D42 Gill Gell devocyte cell-derived chemotaxin -0.77 -0.40 8.91 4.113 fon & heme NO D0.042 NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 tron & heme NO D42 D42 Spleen IL4-silke 1.55 0.61 1.117 -0.64 Igreceptor NO D42 D42 Spleen D40 (TNR5) 1.00 -0.43 0.95 -0.67 Fortease NO D42 NO D42 Gill MHC class Is heavy chain 0.15 1.00 -2.50 0.75 Protease NO D42 NO D42 Gill MAtaisas I hibitatnifgen 0.25 1.</td><td>NO D42 Gill IL-1 receptor type II 0.24 0.75 -2.01 0.81 Polyamic D0,D42 Spleen NO D42 Gill LL-10 receptor beta chain 0.29 0.25 2.22 0.37 Effector NO D42 Gill NO D42 Gill Levkorte cell-derived chemotaxin -0.77 -0.40 8.93 113 Iron & heme NO D0,D242 HK NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Gill D42 Spleen L640 (TNR5) 100 0.43 0.98 1.13 Scavenger NO D42 Gill NO D42 Gill HA class I histamigen 0.25 1.00 -2.50 0.75 Protease NO D42 Gill NO D42 Gill MA class I histamigen 0.25 1.00 2.50 0.75 Protease NO D42</td><td>No De2 Gill Lit Is receptor type II 0.24 0.27 0.20 0.81 Polyamine D0, D42 Gill Ornithine acetyltransferase 1 NO D42 Gill Lit Droceptor beta chain 0.27 0.40 0.31 Effector NO D42 Gill CSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Spleen Lish Iter exceptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Spleen Lish Iter exceptor -0.65 -0.12 1.94 0.72 Iron & heme NO D42 Spleen Lish Iter exceptor -0.64 1.98 -0.64 Iter exceptor NO D42 Gill MMC Class I histantigen 0.15 1.39 -0.68 0.74 Protease NO D42 Gill MMP-13 or Collagenase 3 NO D42 Gill HAC Class I histantigen 0.15 1.39 2.80 0.48 Protease NO D42 Gilll MMP-13 or Collag</td><td>No De2 Gill Lif Jreceptor type II 0.24 0.25 -2.03 0.81 Polyamine D0.042 Spleen Diamine acceptransferase 1 113 NO D42 Gill Leukoropt obstachain 0.27 -0.20 0.37 Effector NO D42 Gill Continine decatbonylose 1 0.46 NO D42 Gill Leukoropt obstachain -0.77 -0.40 2.01 1.04 -0.65 -0.12 1.04 -0.64 greecptor NO D42 Spleen Legitor -0.65 -0.12 1.04 -0.64 greecptor NO D42 Gill Macrophage receptor MARCO 1.07 DA D42 Spleen Code (TNPR5) 1.00 -0.64 0.88 -0.64 precesse NO D42 Gill MMc12 classes 1.03 NO D42 Gill MMF-13 or Collagenase 3 0.037 NO D42 Gill D417 Classe In heav chain -0.18 0.05 Protease NO <t< td=""><td>No Del2 Gill IL:1 receptor type III 0.24 0.75 2.201 0.81 Polyamine D0,042 Spleen Diamine accety/transferase I 1.13 0.36 NO D42 Gill Leir receptor beta chain -0.77 -0.40 3.31 2.11 trans heme NO D0,042 Spleen Method constraints -0.46 0.32 NO D42 Gill Ledvocyte cell-derived chemotaxin -0.77 -0.40 3.31 1.11 form & heme NO D0,22 Spleen Haptoglobin -0.46 0.42 D42 Spleen Cody (TMFK5) -0.00 -0.43 Igr ecceptor NO D42 Gill Metro 3not collagenase 3 1.02 -0.40 NO D42 Gill Mid-class II histantigen 0.25 1.00 2.50 0.75 Protease NO D42 Gill MMP-30 or collagenase 3 0.07 1.31 NO D42 Gill Meta class II histantigen 0.25 1.03 2.53<!--</td--><td>No No Vest Gill IL:11 receptor type III 0.24 0.75 -0.20 0.81 Polyamine D0.042 Splen Diamine acceptionaferase I 1.13 0.96 0.97 NO 0.42 Gill Lit receptor beta chain 0.27 -0.40 2.91 Tron & heme NO 0.02 Splen Hetro organization 0.41 0.43 0.33 NO 0.42 Gill Levocyte cell-derived chemotaxin 4.07 4.04 2.92 Fore explori -0.46 1.82 4.03 4.04 1.81 3.03 0.83 0.85 1.13 Screenger NO 0.42 Gill Mercophage receptor MACO 1.01 3.02 3.03 4.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.04 7.03 7.04 7.03 7.04 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03</td></td></t<></td></td<>	NO D42 Gill IL-1 receptor type II 0.24 NO D42 Gill IL-10 receptor type II 0.24 NO D42 Gill IL-10 receptor type II 0.24 NO D42 Gill Let.0 receptor beta chain 0.27 NO D42 Gill GEV totoptor beta chain 0.97 NO D42 Gill GEV totoptor beta chain 0.05 D42 Spleen CA0 (TNR5) 1.00 D0 Spleen CA0 (TNR5) 0.09 D0 D42 Gill HAC class I heravy chain 0.15 D0 D42 Gill CA0 (TNR5) 0.09 D0 HK Serum amyloid A-5 1.35 D0 HK MC class Ia heavy chain -0.43 D0 HK Serum amyloid A-5 1.35 D0 HK Serum amyloid A-5 1.35 NO D42 Gill Differentially regulated protein 1 1.45 NO D42	NO D42 Gill IL-1 receptor type II 0.24 0.75 NO D42 Gill IL-10 receptor type II 0.29 0.25 NO D42 Gill IL-10 receptor type II 0.29 0.25 NO D42 Gill IL-10 receptor type II 0.77 -0.40 NO D42 Gill GSF receptor -0.65 -0.12 DNO D0 Spleen IL-3/16 1.00 0.43 D0 Spleen Beta-2 microglobulin -0.44 0.98 NO D42 Gill HAL class II histantigen 0.25 1.00 NO D42 Gill HAL class II histantigen -0.25 1.00 NO D42 Gill D40 (TNFR5) -0.31 1.05 D0 HK CH4C (TNFR5) -0.37 1.56 D0 HK Serum amyloid A-5 1.39 0.06 D0 HK Mel class Ia heavy chain -0.43 0.95	NO D42 Gill IL-1 receptor ype II 0.24 0.75 -200 NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 NO D42 Gill GCSF receptor -0.77 -0.40 851 NO D42 Gill GCSF receptor -0.65 -0.12 194 D42 Spleen IL-8-like 1.56 0.61 1.17 D42 Spleen D40 (TIRFS) -0.00 0.43 0.98 -0.90 NO D42 Gill HAL class I histantigen 0.25 1.00 -2.50 NO D42 Gill Beta-2 microglobulin -0.18 0.95 -1.99 D42 Gill MAL class I histantigen 0.25 1.00 -2.50 NO D42 Gill Abolipoprotein C-1 -0.31 1.05 -1.50 D0 H	NO D42 Gill IL-1 receptor byte II 0.24 0.75 -201 0.81 NO D42 Gill IL-10 receptor byte achain 0.29 0.25 1.22 0.37 NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 0.37 NO D42 Gill Levkorte cell-derived chemotaxin 0.77 0.40 891 1113 NO D42 Gill GEV control of the set of t	NO D42 Gill IL-1 receptor ype II 0.24 0.75 201 0.81 Polyamine NO D42 Gill LL-10 receptor beta chain 0.29 0.25 1.22 0.37 Effector NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme D42 Spleen D47 (TNF6) -0.00 0.61 2.17 -0.64 Igreceptor D42 Spleen D47 (TNF6) -0.00 0.80 -0.90 -0.57 Protease NO D42 Gill HAL class II histamigen 0.25 1.00 2.50 0.75 Protease NO D42 Gill Editas II histamigen -0.38 0.65 -0.53 0.89 oxitative burst D0 HK D40 (TNF75) -0.34 0.85 -0.53 0.89 oxitative burst <	NO D42 Gill IL-1 receptor type II 0.24 0.75 2.00 0.81 Polyamine NO D42 Gill IL-10 receptor beta chain 0.29 0.25 1.22 0.37 Effector NO NO D42 Gill GCSF receptor -0.07 -0.40 3.91 Lill ron & heme NO NO D42 GIII GCSF receptor -0.07 -0.40 3.93 Lill ron & heme NO D0 Spleen IL-s-like 1.95 0.61 -1.17 -0.64 Igr receptor NO D04 Spleen D424 GIII MHC class Is heavy chain 0.15 1.39 -2.80 0.75 Protease NO NO D42 GIII HA class II histanifegan 0.25 1.00 -2.80 0.75 Protease NO NO D42 GIII CD40 (TNR5) 0.99 1.11 -1.11 0.38 Protease LO D0 HK	NO D42 Gill IL-1 receptor type II 0.24 0.75 -2.01 0.81 Polyamine D0.042 NO D42 Gill Le 10 receptor beta chain 0.29 0.25 3.22 0.37 Effector NO D42 NO D42 Gill Gell devocyte cell-derived chemotaxin -0.77 -0.40 8.91 4.113 fon & heme NO D0.042 NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 tron & heme NO D42 D42 Spleen IL4-silke 1.55 0.61 1.117 -0.64 Igreceptor NO D42 D42 Spleen D40 (TNR5) 1.00 -0.43 0.95 -0.67 Fortease NO D42 NO D42 Gill MHC class Is heavy chain 0.15 1.00 -2.50 0.75 Protease NO D42 NO D42 Gill MAtaisas I hibitatnifgen 0.25 1.	NO D42 Gill IL-1 receptor type II 0.24 0.75 -2.01 0.81 Polyamic D0,D42 Spleen NO D42 Gill LL-10 receptor beta chain 0.29 0.25 2.22 0.37 Effector NO D42 Gill NO D42 Gill Levkorte cell-derived chemotaxin -0.77 -0.40 8.93 113 Iron & heme NO D0,D242 HK NO D42 Gill GCSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Gill D42 Spleen L640 (TNR5) 100 0.43 0.98 1.13 Scavenger NO D42 Gill NO D42 Gill HA class I histamigen 0.25 1.00 -2.50 0.75 Protease NO D42 Gill NO D42 Gill MA class I histamigen 0.25 1.00 2.50 0.75 Protease NO D42	No De2 Gill Lit Is receptor type II 0.24 0.27 0.20 0.81 Polyamine D0, D42 Gill Ornithine acetyltransferase 1 NO D42 Gill Lit Droceptor beta chain 0.27 0.40 0.31 Effector NO D42 Gill CSF receptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Spleen Lish Iter exceptor -0.65 -0.12 1.94 -0.72 Iron & heme NO D42 Spleen Lish Iter exceptor -0.65 -0.12 1.94 0.72 Iron & heme NO D42 Spleen Lish Iter exceptor -0.64 1.98 -0.64 Iter exceptor NO D42 Gill MMC Class I histantigen 0.15 1.39 -0.68 0.74 Protease NO D42 Gill MMP-13 or Collagenase 3 NO D42 Gill HAC Class I histantigen 0.15 1.39 2.80 0.48 Protease NO D42 Gilll MMP-13 or Collag	No De2 Gill Lif Jreceptor type II 0.24 0.25 -2.03 0.81 Polyamine D0.042 Spleen Diamine acceptransferase 1 113 NO D42 Gill Leukoropt obstachain 0.27 -0.20 0.37 Effector NO D42 Gill Continine decatbonylose 1 0.46 NO D42 Gill Leukoropt obstachain -0.77 -0.40 2.01 1.04 -0.65 -0.12 1.04 -0.64 greecptor NO D42 Spleen Legitor -0.65 -0.12 1.04 -0.64 greecptor NO D42 Gill Macrophage receptor MARCO 1.07 DA D42 Spleen Code (TNPR5) 1.00 -0.64 0.88 -0.64 precesse NO D42 Gill MMc12 classes 1.03 NO D42 Gill MMF-13 or Collagenase 3 0.037 NO D42 Gill D417 Classe In heav chain -0.18 0.05 Protease NO <t< td=""><td>No Del2 Gill IL:1 receptor type III 0.24 0.75 2.201 0.81 Polyamine D0,042 Spleen Diamine accety/transferase I 1.13 0.36 NO D42 Gill Leir receptor beta chain -0.77 -0.40 3.31 2.11 trans heme NO D0,042 Spleen Method constraints -0.46 0.32 NO D42 Gill Ledvocyte cell-derived chemotaxin -0.77 -0.40 3.31 1.11 form & heme NO D0,22 Spleen Haptoglobin -0.46 0.42 D42 Spleen Cody (TMFK5) -0.00 -0.43 Igr ecceptor NO D42 Gill Metro 3not collagenase 3 1.02 -0.40 NO D42 Gill Mid-class II histantigen 0.25 1.00 2.50 0.75 Protease NO D42 Gill MMP-30 or collagenase 3 0.07 1.31 NO D42 Gill Meta class II histantigen 0.25 1.03 2.53<!--</td--><td>No No Vest Gill IL:11 receptor type III 0.24 0.75 -0.20 0.81 Polyamine D0.042 Splen Diamine acceptionaferase I 1.13 0.96 0.97 NO 0.42 Gill Lit receptor beta chain 0.27 -0.40 2.91 Tron & heme NO 0.02 Splen Hetro organization 0.41 0.43 0.33 NO 0.42 Gill Levocyte cell-derived chemotaxin 4.07 4.04 2.92 Fore explori -0.46 1.82 4.03 4.04 1.81 3.03 0.83 0.85 1.13 Screenger NO 0.42 Gill Mercophage receptor MACO 1.01 3.02 3.03 4.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.04 7.03 7.04 7.03 7.04 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03</td></td></t<>	No Del2 Gill IL:1 receptor type III 0.24 0.75 2.201 0.81 Polyamine D0,042 Spleen Diamine accety/transferase I 1.13 0.36 NO D42 Gill Leir receptor beta chain -0.77 -0.40 3.31 2.11 trans heme NO D0,042 Spleen Method constraints -0.46 0.32 NO D42 Gill Ledvocyte cell-derived chemotaxin -0.77 -0.40 3.31 1.11 form & heme NO D0,22 Spleen Haptoglobin -0.46 0.42 D42 Spleen Cody (TMFK5) -0.00 -0.43 Igr ecceptor NO D42 Gill Metro 3not collagenase 3 1.02 -0.40 NO D42 Gill Mid-class II histantigen 0.25 1.00 2.50 0.75 Protease NO D42 Gill MMP-30 or collagenase 3 0.07 1.31 NO D42 Gill Meta class II histantigen 0.25 1.03 2.53 </td <td>No No Vest Gill IL:11 receptor type III 0.24 0.75 -0.20 0.81 Polyamine D0.042 Splen Diamine acceptionaferase I 1.13 0.96 0.97 NO 0.42 Gill Lit receptor beta chain 0.27 -0.40 2.91 Tron & heme NO 0.02 Splen Hetro organization 0.41 0.43 0.33 NO 0.42 Gill Levocyte cell-derived chemotaxin 4.07 4.04 2.92 Fore explori -0.46 1.82 4.03 4.04 1.81 3.03 0.83 0.85 1.13 Screenger NO 0.42 Gill Mercophage receptor MACO 1.01 3.02 3.03 4.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.04 7.03 7.04 7.03 7.04 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03</td>	No No Vest Gill IL:11 receptor type III 0.24 0.75 -0.20 0.81 Polyamine D0.042 Splen Diamine acceptionaferase I 1.13 0.96 0.97 NO 0.42 Gill Lit receptor beta chain 0.27 -0.40 2.91 Tron & heme NO 0.02 Splen Hetro organization 0.41 0.43 0.33 NO 0.42 Gill Levocyte cell-derived chemotaxin 4.07 4.04 2.92 Fore explori -0.46 1.82 4.03 4.04 1.81 3.03 0.83 0.85 1.13 Screenger NO 0.42 Gill Mercophage receptor MACO 1.01 3.02 3.03 4.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.04 7.03 7.04 7.03 7.04 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03

Four DEG with different immune roles showed similar expression profiles in the gill, head kidney, and spleen: an antibacterial peptide cathelicidin (Shinnar et al., 2003), diamine acetyltransferase 1, an enzyme of polyamine metabolism, apolipoprotein c-I, a cholesterol transporter involved in protection against pathogens (Fuior and Gafencu, 2019), and cd40 (tnfr5) a costimulatory protein of antigen presenting cells (Figure 3). Despite similar trends with respect to the treatment groups and time-points, the composition of DEG in the tissues was different. The number of DEG encoding cytokines, chemokines, and receptors was highest in the gill, similar to the genes involved in antigen presentation (respectively, six and four genes). Innate antiviral responses usually show the strongest suppression during smoltification. Four genes from this group [interferon a, and highly active virus responsive genes - VRG (Krasnov et al., 2011b) receptor transporting protein, viperin and isg15] were downregulated in the spleen. Several markers of T cells showed lower expression in the lymphatic organs of NO: cd4 and cd28 in the head kidney and cd28, cd152, and cd274 in the spleen. Difference between the treatment groups involved diverse functional groups and pathways of the immune system.

Challenge With Moritella viscosa

The first mortality in challenged salmon was recorded at 5 dpi in LO fish and at 8 dpi in NO fish (**Figure 4**). The difference peaked at 18% at 20–25 dpi (p < 0.05). At the end of trial

at 36 dpi, mortality remained 10% lower in NO, although not significantly (**Figure 3**). Overall, LO showed a trend toward higher mortality throughout the trial. No significant differences in the mortality were registered in the replicate tanks during the challenge period, and data are presented as mean cumulative mortality of the two tanks.

The magnitude of transcriptome responses to the infection with *M. viscosa* reflected by the numbers of DEG was similar in





the experimental groups and expression changes in the spleen were stronger in comparison with gill (Table 1). In spite of relatively small numbers of immune genes (from 7.7 to 13.1% of all DEG), the terms related to the immune system prevailed among the enriched functional categories of GO (Table 2). The enrichment analysis and inspection of DEG suggested strong and complex defensive responses to the bacterial pathogen. Putative homologs of pathogen recognition Toll-like receptors (tlr12 and tlr8) were upregulated in both tissues (Figure 5) and spleen (Figure 6B), respectively. Lipid mediators seemed to play a key part in cell signaling and communication. Six genes involved in eicosanoid metabolism were upregulated in both tissues (Figure 5). Two genes including phospholipase a2, which releases fatty acids precursors of eicosanoids from phospholipids, were activated in the gill and seven genes were upregulated in the spleen (Figure 6). Concurrent downregulation of four chemokines in the spleen and 11 chemokines in the gill suggested a trade-off between these two signaling systems. Reduced levels of chemokines transcripts in gill also indicated possible migration of immune cells to the infected sites or redistribution of cell populations in this organ. This could explain an apparent downregulation of several immune genes, such as free radicals producing inducible nitric oxide synthase (22- and 10-fold in, respectively, NO and LO fish), cytochrome b245, and neutrophil cytosolic factors - ncf2 (two other ncf2 were upregulated). Similar changes were observed

TABLE 1 The numbers of genes with differential expression between the treatment groups and uninfected and infected fish (microarray analyses).

Contrast	DEG (up/down)
Gill	
Difference between NO and LO, uninfected fish, all genes	654/770
Difference between NO and LO, uninfected fish, immune genes	40/66
Difference between NO and LO, infected fish, all genes	832/964
Difference between NO and LO, infected fish, immune genes	109/57
NO, difference between infected and uninfected fish, all genes	689/900
NO, difference between infected and uninfected fish, immune genes	99/69
LO, difference between infected and uninfected fish, all genes	660/657
LO, difference between infected and uninfected fish, immune genes	121/56
Difference between LO and NO before and after challenge, all genes	298/482
Difference between LO and NO before and after challenge, immune genes	18/27
Spleen	
Difference between NO and LO, uninfected fish, all genes	1,973/1,037
Difference between NO and LO, uninfected fish, immune genes	113/103
Difference between NO and LO, infected fish, all genes	812/954
Difference between NO and LO, infected fish, immune genes	76/69
NO, difference between infected and uninfected fish, all genes	889/564
NO, difference between infected and uninfected fish, immune genes	96/59
LO, difference between infected and uninfected fish, all genes	647/610
LO, difference between infected and uninfected fish, immune genes	137/42
Difference between LO and NO before and after challenge, all genes	480/368
Difference between LO and NO before and after challenge, immune genes	47/12

in the complement factors *c7* and *c8 beta*, *rnase zf-3*, an antibacterial effector with strong expression changes in gill of Atlantic salmon (Zanfardino et al., 2010; Król et al., 2020), and several other immune genes (Figure 5A). The pathogen stimulated both humoral and cellular immune responses. Diverse immune effectors were involved including antibacterial and acute phase proteins, components of the oxidative burst complex, serine and matrix metalloproteases (*mmp 9* and *mmp 13*), and TNF-inducible metalloreductase *steap 4*; a hallmark of Atlantic salmon responses to *M. viscosa* in this trial was upregulation of a large set of *lectins* in both tissues and especially in the spleen. Five genes showed opposite changes in tissues including three *chemokines, cathelicidin*, and *differentially regulated trout protein* (Figure 5).

TABLE 2 Enrichment of functional categories of GO in the list of genes that responded to challenge with *M. viscosa*.

Functional categories of GO	Spleen ¹	Gill ¹	Total ²
Defense response to bacterium	16	<u>25</u>	290
Inflammatory response	<u>68</u>	<u>82</u>	1,001
Chemokine activity	<u>10</u>	<u>15</u>	54
Cytokine activity	13	<u>24</u>	309
Lipoxygenase pathway	<u>7</u>	<u>7</u>	38
Fc-gamma receptor signaling pathway	16	<u>23</u>	326
Chemokine-mediated signaling pathway	<u>9</u>	<u>16</u>	74
Cytokine-mediated signaling pathway	42	59	774
Complement activation	8	<u>14</u>	151
Heme binding	<u>29</u>	<u>28</u>	390
Reactive oxygen species metabolic process	8	14	147
Scavenger receptor activity	18	<u>20</u>	246
Chemotaxis	<u>26</u>	<u>32</u>	314
Monocyte differentiation	<u>10</u>	4	81
Platelet aggregation	9	<u>20</u>	193
Platelet degranulation	28	<u>42</u>	443
Ammonium transport	<u>6</u>	<u>4</u>	18
Bicarbonate transport	<u>12</u>	<u>11</u>	99
Ceramide biosynthetic process	7	<u>9</u>	86
Triglyceride catabolic process	6	<u>8</u>	63
Glycolysis	<u>13</u>	<u>10</u>	107
Mitochondrion	158	168	3,164
Peptidase inhibitor activity	<u>15</u>	<u>13</u>	153
Proteolysis	<u>74</u>	59	1,065
Basement membrane	29	<u>31</u>	413
Laminin binding	10	<u>13</u>	136
Collagen	<u>30</u>	<u>43</u>	344
Collagen catabolic process	<u>13</u>	<u>15</u>	138
Extracellular matrix	80	107	1,004
Focal adhesion	87	<u>106</u>	1,620
Integrin binding	38	<u>49</u>	610
Cell adhesion	<u>126</u>	<u>157</u>	2,110
Osteoblast differentiation	19	<u>32</u>	452
Vasculature development	11	<u>15</u>	184

¹Numbers of DEG per category.

²Number of genes per category on the microarray platform. Significant enrichment (Yates' corrected chi-square) is indicated with underlined italics.

Name	Gill NO	Gill LO	Spleen NO	Spleen LO
Toll-like receptor 12	1.93	3.12	2.94	2.11
Arachidonate 15-lipoxygenase B-like	1.15	0.95	2.13	2.21
Arachidonate 5-lipoxygenase-activating protein	0.65	1.02	<u>1.19</u>	1.44
CYP2J2	0.55	0.86	1.62	1.88
Docosahexaenoic acid omega-hydroxylase	1.31	0.55	1.11	1.07
Epidermis-type lipoxygenase 3	2.20	1.49	2.89	3.82
Hydroperoxide isomerase ALOXE3-like	0.85	0.23	1.60	1.29
Leukotriene A-4 hydrolase	1.07	1.04	<u>0.49</u>	1.23
Leukotriene B4 receptor 1	0.85	0.95	0.89	0.92
C-C motif chemokine 13-like	-2.59	-1.93	-0.80	-1.42
C-C motif chemokine 13-like	-2.25	-1.77	-1.00	-1.27
C-X-C chemokine receptor type 4	0.91	0.95	-1.11	-0.12
Cytokine receptor-like factor 1b	<u>1.51</u>	4.85	4.78	2.52
IL-8 receptor	1.75	2.10	2.00	2.84
interleukin-10 receptor subunit beta-like	<u>0.91</u>	2.61	3.87	2.65
interleukin-22 receptor subunit alpha-2-like	0.89	1.82	1.77	0.82
Carcinoembryonic cell adhesion molecule 2 (ceacam20)	2.10	1.90	3.12	4.02
Cathelicidin	-1.35	-1.03	2.91	2.41
Cytochrome b-245, beta polypeptide	0.94	0.61	0.85	1.76
Differentially regulated trout protein 1	-0.73	-1.32	<u>1.41</u>	0.85
Lysozyme C II	0.81	0.68	<u>0.98</u>	2.14
Myeloperoxidase (mpo)	<u>1.11</u>	1.54	1.88	2.54
Natterin-like protein (5 genes)	1.64	1.48	1.81	2.84
Neutrophil cytosolic factor 1	1.57	2.23	0.98	2.06
Neutrophil cytosolic factor 2	0.99	1.29	0.47	1.38
Fish-egg lectin (2 genes)	1.13	0.61	1.46	3.08
Leukolectin protein	0.86	0.79	1.63	1.74
Mannose-binding protein C (mbl2)	-3.77	-3.26	1.12	0.90
P-selectin-like	1.21	1.42	1.85	2.73
Serine protease 1-like	1.02	0.70	3.00	2.64
Matrix metalloproteinase-9	2.18	3.12	1.84	2.43
MMP 13 or Collagenase 3	1.68	2.19	2.62	3.44
Serine protease 1-like	0.66	<u>1.26</u>	2.74	3.73

FIGURE 5 | Immune genes with responses to *M. viscosa* in gill and spleen (microarrays). Data are log2-ER (expression ratios of infected to uninfected fish). Differential expression is indicated with underlined italics. NO, LO – groups maintained at normal and low dissolved oxygen. The numbers of paralogs are indicated in parentheses.

Among genes that responded to *M. viscosa*, only a few showed differences between the treatment groups (highlighted in **Figures 5**, **6**). The bacterial infection caused minor changes in expression of genes involved in antiviral immunity. However, differences between LO and NO fish increased after challenge, especially in the gill. A panel of genes exceeded the threshold of differential expression; higher expression in LO was shown by three *interferons* and a number of VRG including highly specialized antiviral effectors, such as *receptor transporting protein, gig1-1, ifit5*, and *very large inducible gtpase* (**Figure 7**).

DISCUSSION

Oxygen deficiency, decreased energy production, shifting metabolism toward anaerobic pathways, and accumulation of by-products can affect various biological processes, and the consequences are difficult to predict. The immune system and protection against pathogens are among the main concerns. Comparisons of disease resistance in Atlantic salmon kept at normal and low levels of DO produced different results, such as absence of effect in challenge with salmon alphavirus

Gene	Gill NO	Gill LO	Gene	Spleen NO	Spleen LO
Natural killer cell receptor 2B4	0.44	0.86	Toll-like receptor 8	<u>0.97</u>	<u>1.16</u>
Cytosolic phospholipase A2 gamma	<u>0.73</u>	1.43	15-hydroxyprostaglandin dehydrogenase	1.00	0.71
Hydroperoxide isomerase ALOXE3 (2 genes)	0.49	<u>1.11</u>	Arachidonate 5-lipoxygenase-activating	0.64	<u>1.52</u>
Leukotriene A-4 hydrolase	1.07	1.04	Prostaglandin E synthase	1.08	2.05
Prostaglandin-H2 D-isomerase	-0.60	-1.40	Prostaglandin endoperoxide synthase-1	1.14	<u>0.97</u>
C-C motif chemokine 13-like	-2.59	-1.93	Prostaglandin reductase 1	-0.37	-0.95
C-C motif chemokine 17-like	-1.06	-1.24	C-C chemokine receptor type 7	-1.34	-0.14
C-C motif chemokine 21 (2 genes)	-3.27	-2.87	C-C motif chemokine 13-like	<u>-0.93</u>	-1.04
C-C motif chemokine 25	-1.37	-1.64	C-C motif chemokine 20-like	-1.25	-0.03
C-C motif chemokine 28	-0.61	-1.29	C-C motif chemokine 4-like	-1.24	-0.46
C-C motif chemokine 4 (2genes)	-0.54	0.97	C-X-C motif chemokine 11-like	0.51	0.82
IL17D1	-1.07	-1.60	C-X-C motif chemokine 14	1.29	1.42
TNF10-2	0.98	1.11	LPS-induced TNF-alpha factor	2.01	-0.36
Antimicrobial peptide NK-lysin-like	0.82	1.04	CD209 antigen-like protein C (2 genes)	-0.93	-1.05
Complement component C7-like	-1.73	-1.45	CD209 antigen-like protein D	0.48	1.38
Complement component C8 beta	-1.97	-1.97	C-type lectin	1.00	2.10
Complement component C8 gamma chain (co8g)	<u>0.47</u>	1.08	C-type lectin domain family 4E (2 genes)	0.87	1.19
Angiogenin-1 precursor / RNase ZF3	-2.93	-2.14	C-type lectin domain family 4F (2 genes)	<u>0.53</u>	1.62
Cytochrome b-245, beta polypeptide	-0.36	-0.89	C-type lectin domain family 4M (2 genes)	0.67	<u>1.36</u>
neutrophil cytosol factor 2-like	-1.73	-1.32	C-type mannose receptor 2-like	<u>-0.51</u>	-1.16
Neutrophil cytosolic factor 2 (2 genes)	0.99	1.29	Fish-egg lectin-like (2 genes)	2.05	2.78
Nitric oxide synthase 2, inducible	-4.47	-3.25	Lectin (leca)	<u>0.60</u>	0.86
Ornithine decarboxylase	-1.24	-1.83	Leukolectin protein (II) (2 genes)	<u>1.72</u>	<u>3.09</u>
Perforin-1-like	-1.67	-1.18	Macrophage mannose receptor 1-like	<u>1.58</u>	<u>1.79</u>
scavenger receptor class A member 5-like	-1.02	-0.92	Complement C1q-like protein 4 (2genes)	1.78	<u>2.49</u>
Ladderlectin (2 genes)	0.64	1.37	Serum amyloid A (IFN-induced 44)	<u>1.47</u>	2.36
Mannose-binding protein C (2 genes)	-4.58	-4.28	C-reactive protein similar, pentraxin	<u>0.58</u>	<u>1.76</u>
	n = 9	11.0	Saxitoxin and tetrodotoxin-binding protein 2	1.63	1.37
			Metalloreductase STEAP4	0.58	1.32

FIGURE 6 | Immune genes with responses to *M. viscosa* in either gill (A) or spleen (B). Data are log₂-ER (expression ratios of infected to uninfected). Differential expression is indicated with underlined italics. NO, LO – groups maintained at normal and low dissolved oxygen. The numbers of paralogs are indicated in parentheses.

(Andersen et al., 2010) and accelerated progression of amoebic gill disease (Oldham et al., 2020). To our knowledge, remote effects of hypoxia on the immune system and protection against pathogens in Atlantic salmon have not been reported until present. Disturbances experienced in early development may have both beneficial and detrimental consequences, which can be associated with epigenetic programming (Burgerhout et al., 2017; Liu et al., 2017; Moghadam et al., 2017; Uren Webster et al., 2018; Kelly et al., 2020). The reported research has highlighted the potential for long-term effects of hypoxia on the immunity and disease resistance of Atlantic salmon, although the results from only one study should by no means be generalized.

Smoltification was included in our study as a critical period in the life history of Atlantic salmon when massive endocrine regulation redirects the osmotic balance and induces dramatic changes in metabolism, morphology, and behavior (Barron, 1986; Björnsson et al., 2011). The effect on the immune system remained unknown until recently, though it could be anticipated considering the magnitude of the changes compared to metamorphosis and the key role of cortisol in controlling osmoregulation. Since first publication (Johansson et al., 2016), we have repeatedly observed downregulation of immune genes in Atlantic salmon smolts. Although the trend is consistent, the number and composition of DEG vary substantially, and changes would hardly be detectable without high-throughput transcriptome analyses. In developing the ImCom assay, we selected genes with a high probability of differential expression in order to ensure detection of any possible immune changes. Here, this gene set was sufficient for finding difference between the groups exposed to normoxic or hypoxic conditions in early life, although the composition of the affected genes was different between three analyzed tissues. Most of the DEG showed higher expression in LO fish and changes associated with smoltification were overall weaker in this group. A stimulatory effect of hypoxia is consistent with prevalence of a proactive coping strategy in Atlantic salmon (Damsgård et al., 2019; Rey et al., 2021), which could be established in the course of evolution and further enhanced by breeding and adaptation to the farming environment: hazards induce non-specific activation of diverse defense mechanisms including the immune system.

Gene	LO-NO uninfected gill	LO-NO infected gill	LO-NO uninfected spleen	LO-NO infected spleen
Interferon a2	-0.09	1.13	-0.35	1.23
interferon a3	-0.13	1.22	-0.28	1.03
Interferon g	0.51	0.89	0.13	0.31
Ubiquitin-like protein	0.03	1.84	0.54	1.24
Receptor transporting protein	0.14	1.46	-0.08	2.34
Tyrosine-protein kinase Jak1	1.43	1.32	<u>1.95</u>	1.85
Gig1-1	0.15	1.30	0.29	0.39
Poly polymerase 12-2	-0.77	1.29	<u>-1.00</u>	1.29
interferon-induced very large GTPase 1	0.26	1.29	0.37	1.36
Mx	0.19	1.27	<u>-0.92</u>	1.50
VHSV-induced protein-10	0.85	1.14	0.74	0.98
SOCS1	-0.15	1.12	-0.30	0.71
Fish virus induced TRIM-7	0.98	1.04	0.58	0.51
52 kDa Ro protein-4	0.47	1.00	0.49	1.11
Stat1	0.01	0.99	-0.31	0.93
Fish virus induced TRIM-4	0.25	0.96	0.08	0.76
Thymidylate kinase	0.01	0.93	-0.27	0.83
Poly (ADP-ribose) polymerase family 14	0.66	0.91	0.39	0.42
Placenta-specific gene 8 protein-like	0.38	0.91	0.42	0.78
Filaggrin-2	0.76	0.90	0.50	0.82
Poly [ADP-ribose] polymerase 9	0.40	0.90	-0.03	0.41
IFIT-5	-0.14	0.84	-0.15	0.82
Interferon-induced protein 44-1	0.05	0.82	-0.65	1.49
52 kDa Ro protein	-0.14	0.82	0.22	0.59
	<-2.5 <-1.4 <-0.8	8 <-0.4 0 >	0.4 >0.8 >1	.4 >2.5 >5

FIGURE 7 | Expression of genes involved in innate antiviral responses (VRG). Data are log₂-ER (LO to NO expression ratios). Significant differences are indicated with underlined italics. NO, LO – groups maintained at normal and low dissolved oxygen.

In our experience, the transcriptome analyses find a large scale upregulation of immune genes after exposure to various stressors not related to infections. The consequences of the reduced expression of immune genes in smolts remain unknown, although in theory it may contribute to the increased occurrence of infectious diseases during first several months in the sea. This study conclusively showed that higher expression of immune genes in Atlantic salmon smolts does not necessarily improve disease resistance and may cause, or at least coincide with, higher susceptibility to pathogens.

The challenge trial with *M. viscosa* provided an opportunity to gain insight into the host responses to the pathogen. Transcriptome analyses with a genome-wide microarray showed immune protection from the bacterial pathogen involving many genes with well-known roles. However, with exception of the genes involved in innate antiviral responses, the results revealed only minor differences in expression of immune genes between salmon raised under normoxic and hypoxic conditions. The number of genes with expression differences between LO and NO fish was large, even greater than the number of genes affected with bacterial infection. However, it is not known if and how these differences could be related to disease resistance. Several alternative options can be discussed. The observed stimulation in LO smolts indicates a possible exhaustion of the immune system in the long term, while the activation of proinflammatory genes in the gills of NO smolts might enhance the protective barrier. The difference in survival, especially at the end of the trial, might be too small to be reflected in the transcriptome or depend on events, which are not detected at the gene expression levels, such as production of natural or pathogen-specific antibodies. The difference in survival can be associated with two scenarios: a better state of all or most fish in NO or higher frequency of individuals with impaired protection in LO. If the latter is true, survivors can be similar and transcriptome analyses are not expected to reveal differences. Finally, the higher activity of innate antiviral immunity might indicate an unsuccessful defense strategy in salmon exposed to hypoxia.

CONCLUSION

Hypoxia at early life stages induced sustained effects on the immune system of Atlantic salmon and defense against a pathogenic bacterium. Developmental disturbance increased expression of immune genes and attenuated their downregulation during smoltification. However, these changes did not improve survival of fish after challenge with *M. viscosa*.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm. nih.gov/geo/, GSE171693.

ETHICS STATEMENT

The animal study was reviewed and approved by the Norwegian Food Safety Authority.

AUTHOR CONTRIBUTIONS

L-HJ, EB, AK, HJ, and HT: conceptualization. AK, AR, HL, AB, and HJ: methodology. SA: software. AK: writing—original draft

REFERENCES

- Andersen, L., Hodneland, K., and Nylund, A. (2010). No influence of oxygen levels on pathogenesis and virus shedding in Salmonid alphavirus (SAV)-challenged Atlantic salmon (Salmo salar L.). *Virol. J.* 7:198.
- Barron, M. G. (1986). Endocrine control of smoltification in anadromous salmonids. J. Endocrinol. 108, 313–319. doi: 10.1677/joe.0.1080313
- Beemelmanns, A., Zanuzzo, F. S., Xue, X., Sandrelli, R. M., Rise, M. L., and Gamperl, A. K. (2021). The transcriptomic responses of Atlantic salmon (Salmo salar) to high temperature stress alone, and in combination with moderate hypoxia. *BMC Genom.* 22:261. doi: 10.1186/s12864-021-07464-x
- Björnsson, B. T., Stefansson, S. O., and McCormick, S. D. (2011). Environmental endocrinology of salmon smoltification. *Gen. Comp. Endocrinol.* 170, 290–298. doi: 10.1016/j.ygcen.2010.07.003
- Burgerhout, E., Mommens, M., Johnsen, H., Aunsmo, A., Santi, N., and Andersen, Ø (2017). Genetic background and embryonic temperature affect DNA methylation and expression of myogenin and muscle development in Atlantic salmon (Salmo salar). *PLoS One* 12:e0179918. doi: 10.1371/journal. pone.0179918
- Damsgård, B., Evensen, T. H., Øverli, Ø, Gorissen, M., Ebbesson, L. O. E., Rey, S., et al. (2019). Proactive avoidance behaviour and pace-of-life syndrome in Atlantic salmon. R. Soc. Open Sci. 6:181859. doi: 10.1098/rsos.181859
- Davis, J. C. (1975). Minimal dissolved oxygen requirements of aquatic life with emphasis on Canadian species: a review. J. Fish. Board Can. 32, 2295–2332. doi: 10.1139/f75-268
- Fuior, E. V., and Gafencu, A. V. (2019). Apolipoprotein C1: Its pleiotropic effects in lipid metabolism and beyond. *Int. J. Mol. Sci.* 20:5939. doi: 10.3390/ ijms20235939
- Gamperl, A. K., Ajiboye, O. O., Zanuzzo, F. S., Sandrelli, R. M., Ellen de Fátima, C. P., and Beemelmanns, A. (2020). The impacts of increasing temperature and moderate hypoxia on the production characteristics, cardiac morphology and haematology of Atlantic Salmon (Salmo salar). *Aquaculture* 519:734874. doi: 10.1016/j.aquaculture.2019.734874

preparation. EB and HJ: project administration. L-HJ, EB, HJ, and HT: funding acquisition. All authors contributed to writing and read and agreed with the submitted version of the manuscript.

FUNDING

This study was funded by the National Research Council of Norway (267644) and by the Nofima's Strategic Project 11881 granted by the Research Council of Norway. SA was supported with a grant from I. M. Sechenov Institute of Evolutionary Physiology and Biochemistry (IEPHB RAS, research theme No. AAAA-A18-118012290373-7).

ACKNOWLEDGMENTS

We wish to thank the staff at the Aquaculture Research Station in Tromsø and Mette Wesmajærvi Breiland, Gunhild S. Johansson, Marianne Hansen, and Tina Thesslund for their contributions to this project.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fevo.2021. 722218/full#supplementary-material

- Greig, S. M., Sear, D. A., and Carling, P. A. (2006). A review of factors influencing the availability of dissolved oxygen to incubating salmonid embryos. *Hydrol. Process* 21, 323–334. doi: 10.1002/hyp.6188
- Johansson, L. H., Timmerhaus, G., Afanasyev, S., Jorgensen, S. M., and Krasnov, A. (2016). Smoltification and seawater transfer of Atlantic salmon (Salmo salar L.) is associated with systemic repression of the immune transcriptome. *Fish Shellfish Immunol.* 58, 33–41. doi: 10.1016/j.fsi.2016.09.026
- Karlsen, C., Thorarinsson, R., Wallace, C., Salonius, K., and Midtlyng, P. (2017). Atlantic salmon winter-ulcer disease: Combining mortality and skin ulcer development as clinical efficacy criteria against Moritella viscosa infection. *Aquaculture* 473, 538–544. doi: 10.1016/j.aquaculture.2017.01.035
- Karlsen, C., Ytteborg, E., Timmerhaus, G., Høst, V., Handeland, S., Jørgensen, S. M., et al. (2018). Atlantic salmon skin barrier functions gradually enhance after seawater transfer. *Sci. Rep.* 8:9510.
- Kelly, T., Johnsen, H., Burgerhout, E., Tveiten, H., Thesslund, T., Andersen, Ø, et al. (2020). Low oxygen stress during early development influences regulation of hypoxia-response genes in farmed Atlantic salmon (Salmo salar). G3 (Bethesda) 10, 3179–3188. doi: 10.1534/g3.120.401459
- Kolarevic, J., Aas-Hansen, Ø, Espmark, Å, Baeverfjord, G., Terjesen, B. F., and Damsgård, B. (2016). The use of acoustic acceleration transmitter tags for monitoring of Atlantic salmon swimming activity in recirculating aquaculture systems (RAS). Aquacult. Engin. 72, 30–39. doi: 10.1016/j.aquaeng.2016. 03.002
- Krasnov, A., Afanasyev, S., Nylund, S., and Rebl, A. (2020). Multigene expression assay for assessment of the immune status of Atlantic salmon. *Genes (Basel)* 11:1236. doi: 10.3390/genes11111236
- Krasnov, A., Timmerhaus, G., Afanasyev, S., and Jorgensen, S. M. (2011a). Development and assessment of oligonucleotide microarrays for Atlantic salmon (Salmo salar L.). *Comp. Biochem. Physiol. Part D Genom. Proteomics* 6, 31–38. doi: 10.1016/j.cbd.2010.04.006
- Krasnov, A., Timmerhaus, G., Schiotz, B. L., Torgersen, J., Afanasyev, S., Iliev, D., et al. (2011b). Genomic survey of early responses to viruses in Atlantic salmon, Salmo salar L. *Mol. Immunol.* 49, 163–174. doi: 10.1016/j.molimm.2011.08.007

- Król, E., Noguera, P., Shaw, S., Costelloe, E., Gajardo, K., Valdenegro, V., et al. (2020). Integration of transcriptome, gross morphology and histopathology in the gill of sea farmed Atlantic Salmon (Salmo salar): lessons from multi-site sampling. *Front. Genet.* 11:610. doi: 10.3389/fgene.2020.00610
- Kvamme, B. O., Gadan, K., Finne-Fridell, F., Niklasson, L., Sundh, H., Sundell, K., et al. (2013). Modulation of innate immune responses in Atlantic salmon by chronic hypoxia-induced stress. *Fish Shellfish Immunol.* 34, 55–65. doi: 10.1016/j.fsi.2012.10.006
- Liu, J., Plagnes-Juan, E., Geurden, I., Panserat, S., and Marandel, L. (2017). Exposure to an acute hypoxic stimulus during early life affects the expression of glucose metabolism-related genes at first-feeding in trout. *Sci. Rep.* 7:363.
- Løvoll, M., Wiik-Nielsen, C., Tunsjø, H., Colquhoun, D., Lunder, T., Sørum, H., et al. (2009). Atlantic salmon bath challenged with Moritella viscosa–pathogen invasion and host response. *Fish Shellfish Immunol.* 26, 877–884. doi: 10.1016/ j.fsi.2009.03.019
- Martínez, D., De Lázaro, O., Cortés, P., Oyarzún-Salazar, R., Paschke, K., and Vargas-Chacoff, L. (2020). Hypoxia modulates the transcriptional immunological response in *Oncorhynchus* kisutch. *Fish Shellfish Immunol.* 106, 1042–1051. doi: 10.1016/j.fsi.2020.09.025
- Metcalfe, N. B., Taylor, A. C., and Thorpe, J. E. (1995). Metabolic rate, social status and life-history strategies in Atlantic salmon. *Anim. Behav.* 49, 431–436. doi: 10.1006/anbe.1995.0056
- Moghadam, H. K., Johnsen, H., Robinson, N., Andersen, ØH., Jørgensen, E., Johnsen, H. K., et al. (2017). Impacts of early life stress on the methylome and transcriptome of Atlantic salmon. *Sci. Rep.* 7:5023.
- Mutoloki, S., Cooper, G. A., Marjara, I. S., Koop, B. F., and Evensen, Ø (2010). High gene expression of inflammatory markers and IL-17A correlates with severity of injection site reactions of Atlantic salmon vaccinated with oil-adjuvanted vaccines. *BMC Genom.* 11:336. doi: 10.1186/1471-2164-11-336
- Niklasson, L., Sundh, H., Fridell, F., Taranger, G. L., and Sundell, K. (2011). Disturbance of the intestinal mucosal immune system of farmed Atlantic salmon (Salmo salar), in response to long-term hypoxic conditions. *Fish Shellfish Immunol.* 31, 1072–1080. doi: 10.1016/j.fsi.2011.09.011
- Oldham, T., Dempster, T., Crosbie, P., Adams, M., and Nowak, B. (2020). Cyclic hypoxia exposure accelerates the progression of amoebic gill disease. *Pathogens* 9:597. doi: 10.3390/pathogens9080597
- Oldham, T., Nowak, B., Hvas, M., and Oppedal, F. (2019). Metabolic and functional impacts of hypoxia vary with size in Atlantic salmon. *Comp. Biochem. Physiol. A Mol. Integr. Physiol.* 231, 30–38. doi: 10.1016/j.cbpa.2019.01.012
- Olsvik, P. A., Vikeså, V., Lie, K. K., and Hevrøy, E. M. (2013). Transcriptional responses to temperature and low oxygen stress in Atlantic salmon studied with next-generation sequencing technology. *BMC Genom.* 14:817. doi: 10.1186/ 1471-2164-14-817
- Poynter, S. J., Monjo, A. L., Micheli, G., and DeWitte-Orr, S. J. (2017). Scavengers for bacteria: Rainbow trout have two functional variants of MARCO that bind to gram-negative and -positive bacteria. *Dev. Comp. Immunol.* 77, 95–105. doi: 10.1016/j.dci.2017.07.021
- Randall, D. J., Perry, S. F., and Heming, T. A. (1982). Gas transfer and acid/base regulation in salmonids. *Compar. Biochem. Physiol. Part B* 73, 93–103. doi: 10.1016/0305-0491(82)90203-6
- Remen, M., Oppedal, F., Imsland, A. K., Olsen, R. E., and Torgersen, T. (2013). Hypoxia tolerance thresholds for post-smolt Atlantic salmon: dependency of temperature and hypoxia acclimation. *Aquaculture* 416, 41–47. doi: 10.1016/j. aquaculture.2013.08.024
- Remen, M., Oppedal, F., Torgersen, T., Imsland, A. K., and Olsen, R. E. (2012). Effects of cyclic environmental hypoxia on physiology and feed intake of postsmolt Atlantic salmon: initial responses and acclimation. *Aquaculture* 326, 148–155. doi: 10.1016/j.aquaculture.2011.11.036

- Rey, S., Jin, X., Damsgård, B., Bégout, M. L., and Mackenzie, S. (2021). Analysis across diverse fish species highlights no conserved transcriptome signature for proactive behaviour. *BMC Genom.* 22:33. doi: 10.1186/s12864-020-07 317-z
- Robinson, N. A., Timmerhaus, G., Baranski, M., Andersen, O., Takle, H., and Krasnov, A. (2017). Training the salmon's genes: influence of aerobic exercise, swimming performance and selection on gene expression in Atlantic salmon. *BMC Genom.* 18:971. doi: 10.1186/s12864-017-4361-7
- Shinnar, A. E., Butler, K. L., and Park, H. J. (2003). Cathelicidin family of antimicrobial peptides: proteolytic processing and protease resistance. *Bioorg. Chem.* 31, 425–436. doi: 10.1016/s0045-2068(03)00080-4
- Uren Webster, T. M., Rodriguez-Barreto, D., Martin, S. A. M., Van Oosterhout, C., Orozco-terWengel, P., Cable, J., et al. (2018). Contrasting effects of acute and chronic stress on the transcriptome, epigenome, and immune response of Atlantic salmon. *Epigenetics* 13, 1191–1207. doi: 10.1080/15592294.2018. 1554520
- Wang, S. Y., Lau, K., Lai, K. P., Zhang, J. W., Tse, A. C. K., Li, J. W., et al. (2016). Hypoxia causes transgenerational impairments in reproduction of fish. *Nat. Commun.* 7, 1–9.
- Wang, T., Lefevre, S., Huong, D. T. T., Cong, N. V., and Bayley, M. (2009). The effects of hypoxia on growth and digestion. *Fish Physiol.* 27, 361–396. doi: 10.1016/s1546-5098(08)00008-3
- Wood, A. T., Andrewartha, S. J., Elliott, N. G., Frappell, P. B., and Clark, T. D. (2019). Hypoxia during incubation does not affect aerobic performance or haematology of Atlantic salmon (Salmo salar) when re-exposed in later life. *Conserv. Physiol.* 7:coz088.
- Wood, A. T., Clark, T. D., Elliott, N. G., Frappell, P. B., and Andrewartha, S. J. (2020). The effects of constant and cyclical hypoxia on the survival, growth and metabolic physiology of incubating Atlantic salmon (Salmo salar). *Aquaculture* 527:735449. doi: 10.1016/j.aquaculture.2020.735449
- Zanfardino, A., Pizzo, E., Di Maro, A., Varcamonti, M., and D'Alessio, G. (2010). The bactericidal action on *Escherichia coli* of ZF-RNase-3 is triggered by the suicidal action of the bacterium OmpT protease. *FEBS J.* 277, 1921–1928. doi: 10.1111/j.1742-4658.2010.07614.x
- Zanuzzo, F. S., Beemelmanns, A., Hall, J. R., Rise, M. L., and Gamperl, A. K. (2020). The innate immune response of Atlantic salmon (Salmo salar) is not negatively affected by high temperature and moderate hypoxia. *Front. Immunol.* 11:1009. doi: 10.3389/fimmu.2020.01009

Conflict of Interest: AK, EB, HJ, HT, and L-HJ were employed by company Nofima AS.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Krasnov, Burgerhout, Johnsen, Tveiten, Bakke, Lund, Afanasyev, Rebl and Johansen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.